This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 2,435 trials Clear all
Filter by:

Clinical Study of Platelet-rich Plasma Promoting Tendon-bone Healing in Anterior Cruciate Ligament Reconstruction

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Sports Injury
    Sports Injury
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Platelet-Rich Plasma

Eligibility
  • Ages: 15 to 50 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Platelet-Rich Plasma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

Anterior cruciate ligament (ACL) injury is a common knee injury, which seriously affects the living ability and sport level of the injured. ACL reconstruction is the main method to treat ACL injury. Due to the reconstructive ligament needs a tendon bone healing and ligament maturation, therefore, in the ACL anatomical study, reconstruction surgery and reconstruction materials under the condition of constant progress, how to improve the ACL reconstruction of tendon bone healing and shorten the time of the ligament mature, improve the clinical effect of ACL reconstruction, has become the focus in the ACL reconstruction. Autologous platelet-rich plasma (PRP) is full of growth factors and bioactive factors, which has the function of promoting tissue healing, anti-inflammatory and analgesic effects. At the same time of anterior cruciate ligament reconstruction, using autologous PRP in the bone channel might promote tendon bone healing and ligament maturing after ACL reconstruction, promote the recovery of proprioception, prevent bone channel expanding, shorten the postoperative recovery time, speed up the patients recovery exercise ability, improve the clinical effect of ACL reconstruction. In this study, patients with ACL injuries were randomly divided into two groups: one group underwent ACL anatomical reconstruction, and the other group underwent ACL anatomical reconstruction with PRP. Various clinical scores, KT-2000, Biodex and imaging tests were used to evaluate the differences in the clinical effects of the two surgical methods in terms of postoperative pain, joint swelling, knee function, joint stability, muscle strength recovery, bone channel expanding, ligament vasinization, and ligament maturation.

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Tick-Borne Encephalitis
    Tick-Borne Encephalitis
  • Phase Phase 3
    Phase 3
INTERVENTION

Biological: TBE vaccine 0.5 mL, Biological: TBE vaccine 0.25 mL

Eligibility
  • Ages: 1 Year and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: TBE vaccine 0.5 mL, Biological: TBE vaccine 0.25 mL

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Medical Co. LTA PS Clinic, Fukuoka,, Fukuoka, Japan

Brief Summary

The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.

Combined Treatment With CO2 Laser and Isotretinoin for Acne Scars

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Acne Vulgaris
    Acne Vulgaris
  • Phase Phase 2
    Phase 2
INTERVENTION

Combination Product: Isotretinoin and CO2 laser, Device: Co2 laser

Eligibility
  • Ages: 15 to 60 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Combination Product: Isotretinoin and CO2 laser, Device: Co2 laser

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tel Aviv sourasky medical center, Tel Aviv, Israel

Brief Summary

Isotretinoin is an FDA-approved vitamin A metabolite for the treatment of severe acne; acne that does not respond to other treatments and has a tendency to cause scarring. Ablative laser treatment is another effective treatment against acne scarring. We believe that the combination of CO2 ablative laser treatment with oral isotretinoin for the treatment of scarring is not only safer but also more effective and leads to much more successful cosmetic results.

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Ataxia Telangiectasia
    Ataxia Telangiectasia
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Nicotinamide ribonucleoside

Eligibility
  • Ages: 3 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Nicotinamide ribonucleoside

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hilde Loge Nilsen, Lørenskog, Norway

Brief Summary

The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.

TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Efficacy, Self, Safety Issues
    Efficacy, Self, Safety Issues
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: TQB3525

Eligibility
  • Ages: 12 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: TQB3525

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Peking University Shougang Hospital, Beijing, China

Brief Summary

The PI3K, protein kinase B (AKT), and mTOR signaling network promotes cell growth, survival, metabolism, and motility, but becomes a critical oncogenic driver under aberrant conditions that control the tumor microenvironment and angiogenesis. The PI3K-AKT-mTOR axis is the most frequently deregulated signaling pathway in primary osteosarcoma and other bone tumors. PI3Ka has high rates of 25-50% activating mutations associated with tumor formation in osteosarcoma. Other causes of pathway hyperactivation include loss of function of the tumor suppressor PTEN, gain-of-function mutations in AKT and PDK1, or upregulation of receptor tyrosine kinases. TQB3525 is an orally bioavailable, potent, dual catalytic site inhibitor of PI3Ka and PI3Kd. Tumor growth inhibition has been demonstrated in multiple xenograft osteosarcoma models with PI3K-mutant, PTEN-null cell lines. The investigators try to investigate TQB3525 in primary osteosarcoma and other bone tumors for its safety, tolerability, dose-limiting toxicities (DLT), MTD and antitumor efficacy.

Assessing Health Electronically for Adolescent and Young Adult Oncology

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Risk Reduction Behavior
    Risk Reduction Behavior
  • Phase Phase 1
    Phase 1
INTERVENTION

Behavioral: Check Yourself - Oncology

Eligibility
  • Ages: 13 to 29 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Behavioral: Check Yourself - Oncology

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Seattle Children's, Seattle, Washington, United States

Brief Summary

The purpose of this study is to modify an existing Seattle Children's Hospital investigator-developed, patient-centered, electronic health assessment (eHA) called "Check Yourself" for AYAs with cancer. The investigators will then evaluate the new eHA prototype for feasibility and acceptability among AYAs with cancer and their oncology providers.

Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Biallelic RPE65 Mutation-associated Retinal Dystrophy
    Biallelic RPE65 Mutation-associated Retinal Dystrophy
  • Phase Phase 3
    Phase 3
INTERVENTION

Genetic: voretigene neparvovec

Eligibility
  • Ages: 4 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Genetic: voretigene neparvovec

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Novartis Investigative Site, Meguro-ku, Tokyo, Japan

Brief Summary

The purpose of this study is to provide safety and efficacy data for voretigene neparvovec, administered as subretinal injection, in Japanese patients with biallelic RPE65 mutation-associated retinal dystrophy.

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase Phase 2
    Phase 2
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

Background: The paradigm of combining therapeutic agents with non-overlapping toxicities for the treatment of malignancy produces clinical remissions and cures in a number of tumor types. A new class of agents, humanized and chimerized monoclonal antibodies, typically have little or no hematopoietic toxicity and can be readily combined with full doses of cytotoxic chemotherapy. It has become clear that in certain lymphomas and breast cancers, the combination of monoclonal antibodies and chemotherapy improves response rate and the quality of the response compared with that achieved by treatment with either agent alone. The clinical outcome for patients with T-cell non-Hodgkins lymphoma is significantly inferior to the outcome of patients with B-cell non-Hodgkin s lymphoma. In most reports less than 20% of patients with T cell lymphoid malignancies remain free of disease at 5 years. Objectives: Determine the toxicity of Alemtuzumab and etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) chemotherapy in untreated cluster of differentiation 52 (CD52)-expressing T and natural killer (NK) lymphoid malignancies. Determine the maximum tolerated dose of Alemtuzumab administered in combination with EPOCH chemotherapy. Determine in a preliminary fashion the anti-tumor activity of the combination of Alemtuzumab and EPOCH chemotherapy. Eligibility: CD52-expressing lymphoid malignancy. Patients with chemotherapy naive aggressive T & NK lymphomas. Patients with alk-positive anaplastic large cell lymphoma and patients with T cell precursor disease are not eligible. Age greater than or equal to 17 years. Adequate organ function, unless impairment due to respective organ involvement by tumor. No active symptomatic ischemic heart disease, myocardial infarction or congestive heart. failure within the past year. Human immunodeficiency virus (HIV) negative. Not pregnant or nursing. Design: Three dose levels of Alemtuzumab will be evaluated to determine the toxicity profile and in a preliminary fashion the antitumor activity of the combination with Dose-Adjusted EPOCH. Three dose levels of Alemtuzumab will be explored, in cohorts of three to six patients each. Patients will receive either 30, 60, or 90 mg of Alemtuzumab on day 1 of therapy, followed by dose-adjusted EPOCH chemotherapy days 1-5.

Efficacy and Safety of LH-8 in Paediatric Alopecia Areata

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

Double-blind, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution versus placebo in children and adolescents with moderate to severe scalp alopecia areata. Phase 2/3 study performed in France, Germany, Bulgaria and India in 100 patients.

Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase Phase 3
    Phase 3
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

To evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment intolerant or non-responsive MDR-TB.